ArticleInvestigational new drugs2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534.
Matthew R Chrostek et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it